Investment Thesis
Arcadia Biosciences exhibits severe financial distress with deepening losses despite dramatic revenue growth. The company is burning $1.1M annually in operating cash flow against only $954K in cash reserves, providing less than one year of runway. Negative operating margins of -70.8% and net margins of -398.6% indicate the business model is fundamentally unprofitable and unsustainable without significant operational restructuring or capital infusion.
Strengths
- Strong YoY revenue growth of 2098.2% demonstrates significant top-line acceleration
- Unlevered balance sheet with zero long-term debt reduces financial risk
- Healthy liquidity ratios (3.79x current ratio, 3.17x quick ratio) provide near-term operational flexibility
Risks
- Critical cash runway of approximately 10 months at current -$1.1M annual operating cash burn rate
- Extreme unprofitability across all margins (operating -70.8%, net -398.6%) with no clear path to profitability
- Negative free cash flow of -$1.1M alongside minimal cash reserves of $954K creates existential liquidity risk
- Complete absence of insider buying activity (0 Form 4 filings in 90 days) signals lack of management confidence
- Negative ROE (-152%) and ROA (-82.4%) indicate severe losses relative to equity and asset base
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway until insolvency
- Path to gross profitability and operating break-even timeline
- Quarterly revenue sustainability and gross margin achievement
- Capital raise or debt financing activity to extend runway
Financial Metrics
Revenue
1.1M
Net Income
-4.4M
EPS (Diluted)
$-2.11
Free Cash Flow
-1.1M
Total Assets
5.3M
Cash
954.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-70.8%
Net Margin
-398.6%
ROE
-152.0%
ROA
-82.4%
FCF Margin
-99.9%
Balance Sheet & Liquidity
Current Ratio
3.79x
Quick Ratio
3.17x
Debt/Equity
0.00x
Debt/Assets
45.8%
Interest Coverage
-779.00x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:08:55.564009 |
Data as of: 2026-03-31 |
Powered by Claude AI